Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
BMC Cancer|May 1, 2026
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2<sup>EV</sup> projectAlessandro Rizzo, Francesco Ciccimarra, Stenio de Casio Zequi, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
The New England Journal of Medicine|October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder CancerThomas Powles, Ariel G Kann, Daniel Castellano, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Cell Reports. Medicine|June 23, 2026
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO studyEnrique Grande, Mustafa Sibai, Daniela Grases, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Pageof 6